摘要
目的探讨甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的临床疗效。方法选取2017年2月至2020年6月间中国人民解放军联勤保障部队第九八八医院焦作院区收治的82例晚期胃癌患者,采用随机数表法分为观察组和对照组,每组41例。观察组患者采用甲磺酸阿帕替尼联合多西他赛治疗,对照组患者采用奥沙利铂治疗,比较两组患者治疗前后肿瘤坏死因子(TNF-α)、白介素6(IL-6)、血管内皮生长因子(VEGF)水平、治疗效果及并发症情况。结果观察组患者治疗总有效率为97.6%,高于对照组的85.4%,差异有统计学意义(P<0.05)。治疗前,两组患者TNF-α、IL-6和VEGF水平比较,差异无统计学意义(P>0.05)。治疗后,观察组患者TNF-α、IL-6和VEGF水平均优于对照组,差异均有统计学意义(均P<0.05)。观察组患者不良反应发生率为2.4%,低于对照组的14.6%,差异有统计学意义(P<0.05)。结论甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌患者,效果较好,可降低炎症反应,减少不良反应,值得临床推广使用。
Objective To investigate the therapeutic effect of apatinib mesylate combined with docetaxel as second-line therapy of advanced gastric cancer.Methods Eighty-two patients with advanced gastric cancer admitted to No.988 Hoispital,Joint Logistic Support Force of The Chinese People’s Liberation Army were selected from February 2017 to June 2020.They were catogerized into an observation group and a control group using random number table method with 41 patients in each group.The observation group received apatinib mesylate combined with docetaxel and the control group received oxaliplatin.The levels of tumor necrosis factor(TNF-alpha),interleukin-6(IL-6)and vascular endothelial growth factor(VEGF)were compared before and after the treatment recorded.Treatment efficacy and the incidence of complications were compared between the two groups.Results The overall efficacy rate was 97.6%in the observation group which was significantly higher than 85.4%of the control group(P<0.05).Before the treatment,there was no significant difference in the levels of TNF-alpha,IL-6 and VEGF betwee the two groups(P>0.05).After the treatment,the levels of the levels of TNF-alpha,IL-6 and VEGF were better in the observation group than in the control group(all P<0.05).The overall incidence of complications was 2.4%in the observation group which was significantly lower than 14.6%of the control group(P<0.05).Conclusion Apatinib mesylate combined with docetaxel show high therapeutic effect as secondline treatment of advanced gastric cancer patients,which can reduce the inflammatory reaction and the occurrence of adverse reactions,and it is worthy of clinical promotion.
作者
梁鹏飞
许软成
朱纪彬
王珊珊
白中红
LIANG Peng-fei;XU Ruan-cheng;ZHU Ji-bin;WANG Shan-shan;BAI Zhong-hong(Jiaozuo Campus,No.988 Hoispital,Joint Logistic Support Force of The Chinese People's Liberation Army,Jiaozuo 454003,China)
出处
《中国肿瘤临床与康复》
2021年第7期835-838,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
晚期胃肿瘤
二线治疗
甲磺酸阿帕替尼
多西他赛
奥沙利铂
炎症因子
Advanced gastric neoplasms
Second-line treatment
Apatinib mesylate
Docetaxel
Oxaliplatin
Inflammatory factors
